This is a multicenter, prospective, observational study designed to follow patients with HER2 positive metastatic brease cancer in the United States. Initial diagnosis must be within 6 months of diagnosis. Treatment information is collected every 90 days for approximately 36 months. Patient questionnaire also every 90 days either on site, internet or mail.
